AAAAAA

   
Results: 1-7 |
Results: 7
CD6+donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
Authors: Soiffer, RJ Weller, E Alyea, EP Mauch, P Webb, IL Fisher, DC Freedman, AS Schlossman, RL Gribben, J Lee, S Anderson, KC Marcus, K Stone, RM Antin, JH Ritz, J
Citation: Rj. Soiffer et al., CD6+donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors, J CL ONCOL, 19(4), 2001, pp. 1152-1159
Recovery after stem-cell transplantation for hematologic diseases
Authors: Lee, SJ Fairclough, D Parsons, SK Soiffer, RJ Fisher, DC Schlossman, RL Antin, JH Weeks, JC
Citation: Sj. Lee et al., Recovery after stem-cell transplantation for hematologic diseases, J CL ONCOL, 19(1), 2001, pp. 242-252
Novel therapies targeting the myeloma cell and its bone marrow microenvironment
Authors: Hideshima, T Chauhan, D Podar, K Schlossman, RL Richardson, P Anderson, KC
Citation: T. Hideshima et al., Novel therapies targeting the myeloma cell and its bone marrow microenvironment, SEMIN ONCOL, 28(6), 2001, pp. 607-612
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Authors: Davies, FE Raje, N Hideshima, T Lentzsch, S Young, G Tai, YT Lin, B Podar, K Gupta, D Chauhan, D Treon, SP Richardson, PG Schlossman, RL Morgan, GJ Muller, GW Stirling, DI Anderson, KC
Citation: Fe. Davies et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, BLOOD, 98(1), 2001, pp. 210-216
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Authors: Hideshima, T Chauhan, D Shima, Y Raje, N Davies, FE Tai, YT Treon, SP Lin, B Schlossman, RL Richardson, P Muller, G Stirling, DI Anderson, KC
Citation: T. Hideshima et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, BLOOD, 96(9), 2000, pp. 2943-2950
Predictors of high yield and purity of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma
Authors: Webb, IJ Schlossman, RL Jiroutek, M Doss, D Cohen, CA Freeman, A Schott, DM Anderson, KC
Citation: Ij. Webb et al., Predictors of high yield and purity of CD34(+) cell-selected PBPC, collected from patients with multiple myeloma, CYTOTHERAPY, 1(3), 1999, pp. 175-182
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
Authors: Treon, SP Shima, Y Preffer, FI Doss, DS Ellman, L Schlossman, RL Grossbard, ML Belch, AR Pilarski, LM Anderson, KC
Citation: Sp. Treon et al., Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy, SEMIN ONCOL, 26(5), 1999, pp. 97-106
Risultati: 1-7 |